Recent reports indicate that immune checkpoint blockade antibodies (e.g. anti‐CTLA‐4 and anti‐PD‐1) enhance T cell antitumour activity and have produced exciting and durable results in treatment of a number of cancers 16. Here, CTLA4 is linked to cancer.